Protein-losing enteropathy associated with Henoch-Schönlein purpura

The gastrointestinal manifestations of Henoch-Schönlein purpura include abdominal pain, gastrointestinal bleeding, intussusception, and perforation. Protein-losing enteropathy is rarely associated with Henoch-Schönlein purpura. Two pediatric patients with Henoch-Schönlein purpura who developed protein-losing enteropathy are reported. Tc-99m human serum albumin scintigraphy is useful in the detection of protein-losing enteropathy.


Case Report
Case #1 A 4-year-old boy was hospitalized with colicky abdominal pain. There was no recent drug exposure or immunization, and his family history was unremarkable.
Four days before admission, he had low grade fever and vomiting, and was treated by a family physician. Because of continuing abdominal pain, he was admitted to our hospital with suspected acute gastroenteritis. On admission, he had vomiting and abdominal pain. He was 113 cm tall (±1.63 SD) and weighed 18.4 kg (±0.3 SD). His temperature was 37.4°C, his pulse was 98/min, and his general condition was poor, with abdominal tenderness but no guarding, and no purpura.
On the day after admission, he developed bloody stool and purpura on the lower extremities and scrotum. With a diagnosis of HSP with gastrointestinal involvement, prednisolone (1.5 mg/kg/day), dalteparin (75 U/kg/day), and urinastatin (2,500 U/kg/dose) were started. There was marked edema of eyelids and upper and lower extremities. The patient's serum albumin decreased to 1.8 g/dL, necessitating albumin infusion. His plasma factor XIII activity also decreased to 17%, necessitating human antihemophilic factor XIII fraction. Plasma factor XIII and serum albumin levels normalized by the 10th day. He was discharged on the 35th day.
On plain abdominal CT (Figure 1), diffuse wall thickening in the small bowel and colon and a small amount of ascites were noted.
Tc 99m-human serum albumin (HSA) scintigraphy showed activity in the stomach and duodenum 60 min after injection, suggesting PLE. During the course, no urine abnormalities were detected. His transient hypoproteinemia was likely due to PLE, because it normalized as his abdominal symptoms improved.

Case #2
A 5-year-old boy was admitted with abdominal pain, vomiting, bloody stool, and a rash on his legs. He had no recent drug exposure or immunization, and his family history was unremarkable. Seven days before admission, purpura developed on his nose and around his mouth, followed by abdominal pain and purpura on the upper and lower extremities, involving his buttocks one day later. HSP was diagnosed.
Because of continuing abdominal pain, he was admitted to our hospital. On admission, he had vomiting, abdominal pain, and bloody stool. He was 121.8 cm tall (±1.9 SD) and weighed 22.8 kg (±0.8 SD). His temperature was 36.9°C, pulse was 90/min, and blood pressure was 90/58 mmHg. His general condition was poor, with abdominal tenderness but no guarding, and purpura on the earlobes, lower extremities, and scrotum.
On abdominal CT, diffuse wall thickening was noted in the stomach. Tc-99m-HSA

Figure 1. On abdominal computerized tomography, diffuse wall thickening is noted in the small bowel and colon. A small amount of ascites is seen.
scintigraphy showed activity in the stomach 60 min after injection, suggesting PLE. During the course, no urine abnormalities were detected.

Discussion
Gastrointestinal manifestations of PLE rarely occur with HSP. PLE is a rare condition characterized by gastrointestinal loss of serum protein resulting in hypoproteinemia, which can cause edema, ascites, pleural and pericardial effusions, and malnutrition. Increased capillary permeability or submucosal hemorrhage and ulceration by vasculitis might cause the protein loss. 2 PLE is rare in HSP, with only eight reported pediatric cases, including our two cases [2][3][4][5][6][7] (Table 1). These patients (7 boys, 1 girl; age range, 4 to 14 years) all had abdominal pain; four had several unusual complications (case ## 2, 3, 4, 6). Case #4 5 had abdominal pain, but the stool was Guaiac-negative. Moderate hypoproteinemia (4.9 g/dL) and hypoalbuminemia (2.5 g/dL) without proteinuria were detected during the acute phase; the serum protein levels increased gradually on steroid therapy, but severe neurological involvement resulted from cerebral vasculitis. Case #6, 7 a 4-year-old boy, had severe esophagitis and multiple ulcers in the descending duodenum presenting as PLE. However, our cases had PLE without other complications.
Previously, the detection and quantification of gastrointestinal protein loss primarily involved measurement of fecal excretion of albumin labeled with I-125 or Cr-51 after intravenous tracer injection. However, stool collection is difficult, with false-positive results if the stool specimen is contaminated with urine. Subsequently, measurement of fecal excretion of a1-antitrypsin was used to detect PLE. 8 This serum enzyme, with the same molecular weight as albumin, resists proteolysis and is not degraded when it leaks into the intestinal lumen. However, this is difficult because stool must be collected. Recently, Tc-99m HAS scintigraphy has been used to diagnose PLE by documenting protein loss in the gut, which is also useful for monitoring response to treatment. 9-10 Our two patients were diagnosed as having PLE because of hypoalbuminemia without nephrosis or liver dysfunction, as well as abnormal leakage of the radiotracer into the gut on Tc-99m HSA scintigraphy. Tc-99m HAS scintigraphy offers a rapid, safe, and convenient way to screen and localize PLE. In HSP patients, Tc-99m HSA scintigraphy is useful for detecting PLE.